Trial sponsors are typically responsible for providing the experimental drug or treatment at no cost to patients. However, ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...

TLX591-CDx (Illuccix® in approved jurisdictions, 68 Ga-PSMA-11 ): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index , effective at the close of trading on Friday, December 19, 2025. "Our ...

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation ...

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

More than 50 major insurers have pledged to streamline prior authorization starting in 2026, but providers remain cautiously optimistic and skeptical that the changes will truly reduce burden or ...

As the year comes to a close, the Trump administration seems to be going in two different directions when it comes to the use ...

Strengthen your financial backup. Even with Medicare coverage, unexpected out-of-pocket expenses can pop up. Earn as much as ...